Clinical Trial Update: Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma [Phase 2]

View source ↗

Summary

A Phase 2 trial of tivantinib in previously treated malignant mesothelioma was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelioid Mesothelioma
• Malignant Mesothelioma
• Pleural Mesothelioma
• Sarcomatoid Mesothelioma

Drugs mentioned

• tivantinib (tivantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma | Phase 2 | Status: TERMINATED | Results posted: 2016-10-24